Physician
Oncology
Dr. John F. Dipersio, MD
|
|
Give Review
John Dipersio works in the field of Oncology. He attended University of Rochester School of Medicine and Dentistry. He received 7 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)", "St. Louis Magazine: Top Doctors", "Elected Member" and "Whos Who in Medicine and Healthcare". John Dipersio is a published doctor and has 100 publications published. The lastest was: 'The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia.' John F. Dipersio accepts Medicare payments and is listed with Medicare.gov.
Publications
- Steroids vs. steroids plus additional agent in frontline treatment of Acute graft-versus-host disease: a systematic review and meta-analysis of randomized trials.
- Peri-transplant serum albumin decline predicts subsequent severe Acute graft-versus-host disease following mucotoxic myeloablative conditioning.
- Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
- High-throughput sequencing of cerebrospinal fluid for diagnosis of Chronic Propionibacterium acnes meningitis in an allogeneic stem cell transplant recipient.
- Targeting the leukemia-stroma interaction in Acute myeloid leukemia: rationale and latest evidence.
- Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic st...
- The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.
- Targeting CD123 in AML using a T-Cell directed dual-affinity re-targeting (DART®) platform.
- Outcomes of allogeneic stem cell transplantation in elderly patients with Acute myeloid leukemia: a systematic review and meta-analysis.
- Genomic analysis of germline and somatic variants in familial myelodysplasia/Acute myeloid leukemia.
- [(18)F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility.
- Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
- Role of TP53 mutations in the origin and evolution of therapy-related Acute myeloid leukaemia.
- A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.
- Age-related mutations associated with clonal hematopoietic expansion and malignancies.
- Small molecule inhibitors in Acute myeloid leukemia: from the bench to the clinic.
- Clonal architecture of secondary Acute myeloid leukemia defined by single-cell sequencing.
- Conservative management of pneumatosis intestinalis after allogeneic hematopoietic SCT.
- Haploidentical transplantation using G-CSF-mobilized T-Cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated wi...
- A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.
- Proteasome Inhibitors Evoke Latent Tumor Suppression Programs in Pro-B MLL Leukemias through MLL-AF4.
- Functional heterogeneity of genetically defined subclones in Acute myeloid leukemia.
- Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and Recommendations.
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
- Genomic tools in Acute myeloid leukemia: From the bench to the bedside.
- Phase I study of oral clofarabine consolidation in adults aged 60 and older with Acute myeloid leukemia.
- Advances in stem Cell mobilization.
- Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor Cells in patients ≥60 and <60 years of ag...
- Vorinostat plus tacrolimus and mycophenolate to prevent Graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell ...
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias.
- Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Co...
- Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma.
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
- Role of reduced-intensity conditioning allogeneic hematopoietic stem-Cell transplantation in older patients with de novo myelodysplastic syndromes: an international co...
- The clinical benefit of ruxolitinib across patient subgroups: Analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML.
- Clonal diversity of recurrently mutated genes in Myelodysplastic syndromes.
- Plerixafor Plus Granulocyte Colony-Stimulating Factor Improves the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma and Low Circulating P...
- IFNγR signaling mediates alloreactive T-Cell trafficking and GVHD.
- New hope for mobilization failures . . . Again.
- Clonal evolution in relapsed Acute myeloid leukaemia revealed by whole-genome sequencing.
- Diabetic stem-Cell "mobilopathy".
- Recurrent mutations in the U2AF1 splicing factor in Myelodysplastic syndromes.
- Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem Cells and their mobilization by CXCR4 antagonists in mice.
- Mobilization of hematopoietic stem and Leukemia cells.
- Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and Acute myeloid leukemia: A phase I study.
- Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin Lymphoma treated with standard salvage chemotherapy and autologous stem cell transplanta...
- Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.
- A phase 2 study of high-dose lenalidomide as initial therapy for older patients with Acute myeloid leukemia.
- DNMT3A mutations in Acute myeloid leukemia.
- Transplanted CD34(+) Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hod...
- Relevance and Clinical Implications of Tumor Cell Mobilization in the Autologous Transplant Setting.
- Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for Acute myeloid leukemia in first remission with unfavorable cytogeneti...
- In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-Leukemia.
- Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor Cells.
- Allogeneic transplantation for therapy-related myelodysplastic syndrome and Acute myeloid leukemia.
- Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute myeloid leukemia.
- Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin Lymphoma: results from the pleri...
- Next-generation sequencing of Cancer genomes: back to the future.
- Salvage therapy for Acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF.
- Recurring mutations found by sequencing an Acute myeloid leukemia genome.
- A phase II study of 5-day intravenous azacitidine in patients with Myelodysplastic syndromes.
- BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor Cells.
- Acquired copy number alterations in adult Acute myeloid leukemia genomes.
- Cladribine in the treatment of Acute myeloid leukemia: a single-institution experience.
- Chemosensitization of Acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.
- CXCR4 and mobilization of hematopoietic precursors.
- Role of hematopoietic stem cell transplantation in Acute myelogenous leukemia and myelodysplastic syndrome.
- Total body irradiation before an allogeneic stem Cell transplantation: is there a magic dose?
- Impact of mobilization and remobilization strategies on achieving sufficient stem Cell yields for autologous transplantation.
- Rapid mobilization of functional donor hematopoietic Cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction.
- Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin Lymphoma.
- A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malign...
- Identification of somatic JAK1 mutations in patients with Acute myeloid leukemia.
- Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo Acute myeloid leukemia.
- Therapy options in imatinib failures.
- Bortezomib inhibits osteoclast activity in patients with multiple myeloma.
- A randomized double-blind trial of hydroxychloroquine for the prevention of Chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
- Human progenitor Cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to Cells from the same donor mobilized by granulocy...
- Severity of Clostridium difficile-associated disease (CDAD) in allogeneic stem cell transplant recipients: evaluation of a CDAD severity grading System.
- Commonly dysregulated genes in murine APL Cells.
- Cytokines and hematopoietic stem Cell mobilization.
- Long-term remissions in patients with myelodysplastic syndrome and secondary Acute myelogenous leukemia undergoing allogeneic transplantation following a reduced inten...
- Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor Cell transplantation result in...
- The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor Cell mobilization is superior to G-CSF alone.
- Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's Lymphoma.
- Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-Leukemia after allogeneic bone marr...
- Stem cell transplantation in Acute myelogenous leukemia in first remission: what are the options?
- Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's Lymphoma.
- A pilot study of high-throughput, sequence-based mutational profiling of primary human Acute myeloid leukemia cell genomes.
- Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid Leukemia?
- High-penetrance mouse model of Acute promyelocytic leukemia with very low levels of PML-RARalpha expression.
- Transduction and selection of human T cells with novel CD34/thymidine kinase chimeric suicide genes for the treatment of Graft-versus-host disease.
- Risk factors for Stenotrophomonas maltophilia bacteremia in oncology patients: a case-control study.
- Donor CMV serostatus has no impact on CMV viremia or Disease when prophylactic granulocyte transfusions are given following allogeneic peripheral blood stem cell trans...
- Use of the anti-idiotype breast Cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast Cancer.
- Recent advances in allogeneic hematopoietic stem-Cell transplantation.
- The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal Acute myeloid leukemia.
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- St. Louis Magazine: Top Doctors
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
VA Greater Los Angeles Healthcare System -
University of Rochester School of Medicine and Dentistry
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1730106295 | |
| NPPES Provider LastName | DIPERSIO | |
| NPPES Provider FirstName | JOHN | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 1648.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 63.0 | |
| Percent Opioid Claims | 3.82 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1730106295 |
| Last Name Of The Provider | DIPERSIO |
| First Name Of The Provider | JOHN |
| View All |
Similar Doctors
|
|
Dr. Vanee Wongsurawat, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vikram C. Gorantla, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nancy L. Bartlett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramaswamy Govindan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vorachart Auethavekiat, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alaa A. Elbendary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ravi Vij, MD
This Doctor is OpenDoctor Recommended.
|